nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefotaxime—SLC22A11—Methotrexate—testicular cancer	0.203	0.34	CbGbCtD
Cefotaxime—SLC22A7—Methotrexate—testicular cancer	0.193	0.324	CbGbCtD
Cefotaxime—SLC22A8—Methotrexate—testicular cancer	0.118	0.198	CbGbCtD
Cefotaxime—SLC22A6—Methotrexate—testicular cancer	0.0822	0.138	CbGbCtD
Cefotaxime—Thrombocytopenia—Chlorambucil—testicular cancer	0.0017	0.0042	CcSEcCtD
Cefotaxime—Liver injury—Epirubicin—testicular cancer	0.00169	0.00418	CcSEcCtD
Cefotaxime—Convulsion—Vinblastine—testicular cancer	0.00169	0.00417	CcSEcCtD
Cefotaxime—Agranulocytosis—Ifosfamide—testicular cancer	0.00168	0.00415	CcSEcCtD
Cefotaxime—Erythema multiforme—Dactinomycin—testicular cancer	0.00166	0.00412	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.00166	0.00411	CcSEcCtD
Cefotaxime—Discomfort—Vinblastine—testicular cancer	0.00164	0.00405	CcSEcCtD
Cefotaxime—Haemoglobin—Ifosfamide—testicular cancer	0.00162	0.00401	CcSEcCtD
Cefotaxime—Hepatitis—Ifosfamide—testicular cancer	0.00161	0.00399	CcSEcCtD
Cefotaxime—Haemorrhage—Ifosfamide—testicular cancer	0.00161	0.00399	CcSEcCtD
Cefotaxime—Bronchospasm—Etoposide—testicular cancer	0.00157	0.00388	CcSEcCtD
Cefotaxime—Liver injury—Doxorubicin—testicular cancer	0.00156	0.00387	CcSEcCtD
Cefotaxime—Thrombocytopenia—Vinblastine—testicular cancer	0.00155	0.00385	CcSEcCtD
Cefotaxime—Erythema multiforme—Ifosfamide—testicular cancer	0.00152	0.00378	CcSEcCtD
Cefotaxime—Ill-defined disorder—Bleomycin—testicular cancer	0.00152	0.00377	CcSEcCtD
Cefotaxime—Renal failure—Cisplatin—testicular cancer	0.00152	0.00377	CcSEcCtD
Cefotaxime—Vaginal inflammation—Methotrexate—testicular cancer	0.00152	0.00376	CcSEcCtD
Cefotaxime—Neutropenia—Etoposide—testicular cancer	0.00149	0.00368	CcSEcCtD
Cefotaxime—Malaise—Bleomycin—testicular cancer	0.00148	0.00367	CcSEcCtD
Cefotaxime—Pain—Chlorambucil—testicular cancer	0.00148	0.00367	CcSEcCtD
Cefotaxime—Leukopenia—Bleomycin—testicular cancer	0.00147	0.00364	CcSEcCtD
Cefotaxime—Arrhythmia—Ifosfamide—testicular cancer	0.00144	0.00357	CcSEcCtD
Cefotaxime—Vaginal infection—Methotrexate—testicular cancer	0.00143	0.00355	CcSEcCtD
Cefotaxime—Feeling abnormal—Chlorambucil—testicular cancer	0.00143	0.00353	CcSEcCtD
Cefotaxime—Aplastic anaemia—Methotrexate—testicular cancer	0.00143	0.00353	CcSEcCtD
Cefotaxime—Vaginal inflammation—Epirubicin—testicular cancer	0.00142	0.00352	CcSEcCtD
Cefotaxime—Ill-defined disorder—Dactinomycin—testicular cancer	0.00142	0.00352	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00142	0.00351	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.00141	0.00348	CcSEcCtD
Cefotaxime—Renal failure—Etoposide—testicular cancer	0.00139	0.00345	CcSEcCtD
Cefotaxime—Jaundice—Etoposide—testicular cancer	0.00138	0.00342	CcSEcCtD
Cefotaxime—Discomfort—Bleomycin—testicular cancer	0.00138	0.00342	CcSEcCtD
Cefotaxime—Malaise—Dactinomycin—testicular cancer	0.00138	0.00342	CcSEcCtD
Cefotaxime—Urticaria—Chlorambucil—testicular cancer	0.00138	0.00341	CcSEcCtD
Cefotaxime—Leukopenia—Dactinomycin—testicular cancer	0.00137	0.0034	CcSEcCtD
Cefotaxime—Abdominal pain—Chlorambucil—testicular cancer	0.00137	0.00339	CcSEcCtD
Cefotaxime—Body temperature increased—Chlorambucil—testicular cancer	0.00137	0.00339	CcSEcCtD
Cefotaxime—Colitis—Epirubicin—testicular cancer	0.00137	0.00338	CcSEcCtD
Cefotaxime—Pain—Vinblastine—testicular cancer	0.00136	0.00336	CcSEcCtD
Cefotaxime—Candida infection—Epirubicin—testicular cancer	0.00136	0.00336	CcSEcCtD
Cefotaxime—Vaginal infection—Epirubicin—testicular cancer	0.00134	0.00332	CcSEcCtD
Cefotaxime—Anaphylactic shock—Bleomycin—testicular cancer	0.00134	0.00332	CcSEcCtD
Cefotaxime—Aplastic anaemia—Epirubicin—testicular cancer	0.00133	0.00331	CcSEcCtD
Cefotaxime—Agranulocytosis—Etoposide—testicular cancer	0.00132	0.00328	CcSEcCtD
Cefotaxime—Vaginal inflammation—Doxorubicin—testicular cancer	0.00132	0.00326	CcSEcCtD
Cefotaxime—Thrombocytopenia—Bleomycin—testicular cancer	0.00131	0.00325	CcSEcCtD
Cefotaxime—Feeling abnormal—Vinblastine—testicular cancer	0.00131	0.00324	CcSEcCtD
Cefotaxime—Ill-defined disorder—Ifosfamide—testicular cancer	0.0013	0.00323	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Vinblastine—testicular cancer	0.0013	0.00321	CcSEcCtD
Cefotaxime—Discomfort—Dactinomycin—testicular cancer	0.00129	0.00319	CcSEcCtD
Cefotaxime—Angioedema—Ifosfamide—testicular cancer	0.00128	0.00318	CcSEcCtD
Cefotaxime—Hypersensitivity—Chlorambucil—testicular cancer	0.00128	0.00316	CcSEcCtD
Cefotaxime—Malaise—Ifosfamide—testicular cancer	0.00127	0.00313	CcSEcCtD
Cefotaxime—Colitis—Doxorubicin—testicular cancer	0.00126	0.00313	CcSEcCtD
Cefotaxime—Leukopenia—Ifosfamide—testicular cancer	0.00126	0.00311	CcSEcCtD
Cefotaxime—Candida infection—Doxorubicin—testicular cancer	0.00126	0.00311	CcSEcCtD
Cefotaxime—Abdominal pain—Vinblastine—testicular cancer	0.00125	0.00311	CcSEcCtD
Cefotaxime—Arrhythmia—Cisplatin—testicular cancer	0.00124	0.00308	CcSEcCtD
Cefotaxime—Vaginal infection—Doxorubicin—testicular cancer	0.00124	0.00308	CcSEcCtD
Cefotaxime—Aplastic anaemia—Doxorubicin—testicular cancer	0.00124	0.00306	CcSEcCtD
Cefotaxime—Pruritus—Chlorambucil—testicular cancer	0.00123	0.00303	CcSEcCtD
Cefotaxime—Thrombocytopenia—Dactinomycin—testicular cancer	0.00122	0.00303	CcSEcCtD
Cefotaxime—Convulsion—Ifosfamide—testicular cancer	0.00122	0.00301	CcSEcCtD
Cefotaxime—Erythema multiforme—Etoposide—testicular cancer	0.0012	0.00298	CcSEcCtD
Cefotaxime—Diarrhoea—Chlorambucil—testicular cancer	0.00119	0.00293	CcSEcCtD
Cefotaxime—Hepatic function abnormal—Epirubicin—testicular cancer	0.00118	0.00292	CcSEcCtD
Cefotaxime—Discomfort—Ifosfamide—testicular cancer	0.00118	0.00292	CcSEcCtD
Cefotaxime—Hypersensitivity—Vinblastine—testicular cancer	0.00117	0.0029	CcSEcCtD
Cefotaxime—Pain—Bleomycin—testicular cancer	0.00115	0.00284	CcSEcCtD
Cefotaxime—Anaphylactic shock—Ifosfamide—testicular cancer	0.00115	0.00284	CcSEcCtD
Cefotaxime—Ill-defined disorder—Cisplatin—testicular cancer	0.00112	0.00278	CcSEcCtD
Cefotaxime—Thrombocytopenia—Ifosfamide—testicular cancer	0.00112	0.00278	CcSEcCtD
Cefotaxime—Feeling abnormal—Bleomycin—testicular cancer	0.0011	0.00274	CcSEcCtD
Cefotaxime—Vomiting—Chlorambucil—testicular cancer	0.0011	0.00273	CcSEcCtD
Cefotaxime—Hepatic function abnormal—Doxorubicin—testicular cancer	0.00109	0.00271	CcSEcCtD
Cefotaxime—Malaise—Cisplatin—testicular cancer	0.00109	0.0027	CcSEcCtD
Cefotaxime—Diarrhoea—Vinblastine—testicular cancer	0.00109	0.00269	CcSEcCtD
Cefotaxime—Renal impairment—Epirubicin—testicular cancer	0.00108	0.00269	CcSEcCtD
Cefotaxime—Leukopenia—Cisplatin—testicular cancer	0.00108	0.00268	CcSEcCtD
Cefotaxime—Dermatitis bullous—Epirubicin—testicular cancer	0.00108	0.00267	CcSEcCtD
Cefotaxime—Pain—Dactinomycin—testicular cancer	0.00107	0.00265	CcSEcCtD
Cefotaxime—Urticaria—Bleomycin—testicular cancer	0.00106	0.00264	CcSEcCtD
Cefotaxime—Body temperature increased—Bleomycin—testicular cancer	0.00106	0.00262	CcSEcCtD
Cefotaxime—Convulsion—Cisplatin—testicular cancer	0.00105	0.0026	CcSEcCtD
Cefotaxime—Feeling abnormal—Dactinomycin—testicular cancer	0.00103	0.00255	CcSEcCtD
Cefotaxime—Nausea—Chlorambucil—testicular cancer	0.00103	0.00255	CcSEcCtD
Cefotaxime—Ill-defined disorder—Etoposide—testicular cancer	0.00103	0.00255	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00102	0.00253	CcSEcCtD
Cefotaxime—Discomfort—Cisplatin—testicular cancer	0.00102	0.00252	CcSEcCtD
Cefotaxime—Vomiting—Vinblastine—testicular cancer	0.00101	0.0025	CcSEcCtD
Cefotaxime—Renal impairment—Doxorubicin—testicular cancer	0.001	0.00248	CcSEcCtD
Cefotaxime—Malaise—Etoposide—testicular cancer	0.001	0.00248	CcSEcCtD
Cefotaxime—Dermatitis bullous—Doxorubicin—testicular cancer	0.000999	0.00247	CcSEcCtD
Cefotaxime—Headache—Vinblastine—testicular cancer	0.000994	0.00246	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000993	0.00246	CcSEcCtD
Cefotaxime—Leukopenia—Etoposide—testicular cancer	0.000992	0.00246	CcSEcCtD
Cefotaxime—Abdominal pain—Dactinomycin—testicular cancer	0.000988	0.00245	CcSEcCtD
Cefotaxime—Body temperature increased—Dactinomycin—testicular cancer	0.000988	0.00245	CcSEcCtD
Cefotaxime—Anaphylactic shock—Cisplatin—testicular cancer	0.000988	0.00245	CcSEcCtD
Cefotaxime—Hypersensitivity—Bleomycin—testicular cancer	0.000988	0.00245	CcSEcCtD
Cefotaxime—Pain—Ifosfamide—testicular cancer	0.00098	0.00243	CcSEcCtD
Cefotaxime—Thrombocytopenia—Cisplatin—testicular cancer	0.000967	0.00239	CcSEcCtD
Cefotaxime—Convulsion—Etoposide—testicular cancer	0.000961	0.00238	CcSEcCtD
Cefotaxime—Pruritus—Bleomycin—testicular cancer	0.000948	0.00235	CcSEcCtD
Cefotaxime—Feeling abnormal—Ifosfamide—testicular cancer	0.000944	0.00234	CcSEcCtD
Cefotaxime—Eosinophilia—Methotrexate—testicular cancer	0.000944	0.00234	CcSEcCtD
Cefotaxime—Nausea—Vinblastine—testicular cancer	0.000943	0.00233	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000937	0.00232	CcSEcCtD
Cefotaxime—Discomfort—Etoposide—testicular cancer	0.000933	0.00231	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000929	0.0023	CcSEcCtD
Cefotaxime—Hypersensitivity—Dactinomycin—testicular cancer	0.000921	0.00228	CcSEcCtD
Cefotaxime—Urticaria—Ifosfamide—testicular cancer	0.00091	0.00225	CcSEcCtD
Cefotaxime—Abdominal pain—Ifosfamide—testicular cancer	0.000906	0.00224	CcSEcCtD
Cefotaxime—Body temperature increased—Ifosfamide—testicular cancer	0.000906	0.00224	CcSEcCtD
Cefotaxime—Anaphylactic shock—Etoposide—testicular cancer	0.000905	0.00224	CcSEcCtD
Cefotaxime—Neutropenia—Methotrexate—testicular cancer	0.000891	0.00221	CcSEcCtD
Cefotaxime—Thrombocytopenia—Etoposide—testicular cancer	0.000886	0.00219	CcSEcCtD
Cefotaxime—Eosinophilia—Epirubicin—testicular cancer	0.000883	0.00219	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00086	0.00213	CcSEcCtD
Cefotaxime—Diarrhoea—Dactinomycin—testicular cancer	0.000855	0.00212	CcSEcCtD
Cefotaxime—Vomiting—Bleomycin—testicular cancer	0.000852	0.00211	CcSEcCtD
Cefotaxime—Rash—Bleomycin—testicular cancer	0.000845	0.00209	CcSEcCtD
Cefotaxime—Pain—Cisplatin—testicular cancer	0.000845	0.00209	CcSEcCtD
Cefotaxime—Dermatitis—Bleomycin—testicular cancer	0.000844	0.00209	CcSEcCtD
Cefotaxime—Hypersensitivity—Ifosfamide—testicular cancer	0.000844	0.00209	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000843	0.00209	CcSEcCtD
Cefotaxime—Renal failure—Methotrexate—testicular cancer	0.000835	0.00207	CcSEcCtD
Cefotaxime—Neutropenia—Epirubicin—testicular cancer	0.000834	0.00207	CcSEcCtD
Cefotaxime—Eosinophilia—Doxorubicin—testicular cancer	0.000817	0.00202	CcSEcCtD
Cefotaxime—Feeling abnormal—Cisplatin—testicular cancer	0.000814	0.00202	CcSEcCtD
Cefotaxime—Pruritus—Ifosfamide—testicular cancer	0.000811	0.00201	CcSEcCtD
Cefotaxime—Nausea—Bleomycin—testicular cancer	0.000796	0.00197	CcSEcCtD
Cefotaxime—Vomiting—Dactinomycin—testicular cancer	0.000795	0.00197	CcSEcCtD
Cefotaxime—Agranulocytosis—Methotrexate—testicular cancer	0.000793	0.00196	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000788	0.00195	CcSEcCtD
Cefotaxime—Rash—Dactinomycin—testicular cancer	0.000788	0.00195	CcSEcCtD
Cefotaxime—Diarrhoea—Ifosfamide—testicular cancer	0.000784	0.00194	CcSEcCtD
Cefotaxime—Renal failure—Epirubicin—testicular cancer	0.000782	0.00194	CcSEcCtD
Cefotaxime—Body temperature increased—Cisplatin—testicular cancer	0.000781	0.00193	CcSEcCtD
Cefotaxime—Jaundice—Epirubicin—testicular cancer	0.000775	0.00192	CcSEcCtD
Cefotaxime—Pain—Etoposide—testicular cancer	0.000774	0.00192	CcSEcCtD
Cefotaxime—Neutropenia—Doxorubicin—testicular cancer	0.000772	0.00191	CcSEcCtD
Cefotaxime—Haemoglobin—Methotrexate—testicular cancer	0.000767	0.0019	CcSEcCtD
Cefotaxime—Haemorrhage—Methotrexate—testicular cancer	0.000763	0.00189	CcSEcCtD
Cefotaxime—Hepatitis—Methotrexate—testicular cancer	0.000763	0.00189	CcSEcCtD
Cefotaxime—Feeling abnormal—Etoposide—testicular cancer	0.000746	0.00185	CcSEcCtD
Cefotaxime—Nausea—Dactinomycin—testicular cancer	0.000743	0.00184	CcSEcCtD
Cefotaxime—Agranulocytosis—Epirubicin—testicular cancer	0.000742	0.00184	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Etoposide—testicular cancer	0.00074	0.00183	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00073	0.00181	CcSEcCtD
Cefotaxime—Vomiting—Ifosfamide—testicular cancer	0.000728	0.0018	CcSEcCtD
Cefotaxime—Hypersensitivity—Cisplatin—testicular cancer	0.000728	0.0018	CcSEcCtD
Cefotaxime—Renal failure—Doxorubicin—testicular cancer	0.000723	0.00179	CcSEcCtD
Cefotaxime—Rash—Ifosfamide—testicular cancer	0.000722	0.00179	CcSEcCtD
Cefotaxime—Dermatitis—Ifosfamide—testicular cancer	0.000722	0.00179	CcSEcCtD
Cefotaxime—Erythema multiforme—Methotrexate—testicular cancer	0.000721	0.00179	CcSEcCtD
Cefotaxime—Urticaria—Etoposide—testicular cancer	0.000719	0.00178	CcSEcCtD
Cefotaxime—Haemoglobin—Epirubicin—testicular cancer	0.000718	0.00178	CcSEcCtD
Cefotaxime—Jaundice—Doxorubicin—testicular cancer	0.000717	0.00178	CcSEcCtD
Cefotaxime—Abdominal pain—Etoposide—testicular cancer	0.000715	0.00177	CcSEcCtD
Cefotaxime—Body temperature increased—Etoposide—testicular cancer	0.000715	0.00177	CcSEcCtD
Cefotaxime—Haemorrhage—Epirubicin—testicular cancer	0.000714	0.00177	CcSEcCtD
Cefotaxime—Hepatitis—Epirubicin—testicular cancer	0.000714	0.00177	CcSEcCtD
Cefotaxime—Agranulocytosis—Doxorubicin—testicular cancer	0.000687	0.0017	CcSEcCtD
Cefotaxime—Nausea—Ifosfamide—testicular cancer	0.000681	0.00169	CcSEcCtD
Cefotaxime—Diarrhoea—Cisplatin—testicular cancer	0.000676	0.00167	CcSEcCtD
Cefotaxime—Erythema multiforme—Epirubicin—testicular cancer	0.000675	0.00167	CcSEcCtD
Cefotaxime—Hypersensitivity—Etoposide—testicular cancer	0.000667	0.00165	CcSEcCtD
Cefotaxime—Haemoglobin—Doxorubicin—testicular cancer	0.000664	0.00164	CcSEcCtD
Cefotaxime—Haemorrhage—Doxorubicin—testicular cancer	0.000661	0.00164	CcSEcCtD
Cefotaxime—Hepatitis—Doxorubicin—testicular cancer	0.000661	0.00164	CcSEcCtD
Cefotaxime—Pruritus—Etoposide—testicular cancer	0.00064	0.00159	CcSEcCtD
Cefotaxime—Arrhythmia—Epirubicin—testicular cancer	0.000638	0.00158	CcSEcCtD
Cefotaxime—Vomiting—Cisplatin—testicular cancer	0.000628	0.00156	CcSEcCtD
Cefotaxime—Erythema multiforme—Doxorubicin—testicular cancer	0.000625	0.00155	CcSEcCtD
Cefotaxime—Rash—Cisplatin—testicular cancer	0.000623	0.00154	CcSEcCtD
Cefotaxime—Dermatitis—Cisplatin—testicular cancer	0.000622	0.00154	CcSEcCtD
Cefotaxime—Diarrhoea—Etoposide—testicular cancer	0.000619	0.00153	CcSEcCtD
Cefotaxime—Ill-defined disorder—Methotrexate—testicular cancer	0.000616	0.00153	CcSEcCtD
Cefotaxime—Malaise—Methotrexate—testicular cancer	0.000599	0.00148	CcSEcCtD
Cefotaxime—Leukopenia—Methotrexate—testicular cancer	0.000594	0.00147	CcSEcCtD
Cefotaxime—Arrhythmia—Doxorubicin—testicular cancer	0.00059	0.00146	CcSEcCtD
Cefotaxime—Nausea—Cisplatin—testicular cancer	0.000587	0.00145	CcSEcCtD
Cefotaxime—Ill-defined disorder—Epirubicin—testicular cancer	0.000577	0.00143	CcSEcCtD
Cefotaxime—Convulsion—Methotrexate—testicular cancer	0.000575	0.00142	CcSEcCtD
Cefotaxime—Vomiting—Etoposide—testicular cancer	0.000575	0.00142	CcSEcCtD
Cefotaxime—Rash—Etoposide—testicular cancer	0.000571	0.00141	CcSEcCtD
Cefotaxime—Dermatitis—Etoposide—testicular cancer	0.00057	0.00141	CcSEcCtD
Cefotaxime—Headache—Etoposide—testicular cancer	0.000567	0.0014	CcSEcCtD
Cefotaxime—Malaise—Epirubicin—testicular cancer	0.00056	0.00139	CcSEcCtD
Cefotaxime—Discomfort—Methotrexate—testicular cancer	0.000559	0.00138	CcSEcCtD
Cefotaxime—Leukopenia—Epirubicin—testicular cancer	0.000556	0.00138	CcSEcCtD
Cefotaxime—Anaphylactic shock—Methotrexate—testicular cancer	0.000542	0.00134	CcSEcCtD
Cefotaxime—Convulsion—Epirubicin—testicular cancer	0.000538	0.00133	CcSEcCtD
Cefotaxime—Nausea—Etoposide—testicular cancer	0.000537	0.00133	CcSEcCtD
Cefotaxime—Ill-defined disorder—Doxorubicin—testicular cancer	0.000534	0.00132	CcSEcCtD
Cefotaxime—Thrombocytopenia—Methotrexate—testicular cancer	0.000531	0.00131	CcSEcCtD
Cefotaxime—Discomfort—Epirubicin—testicular cancer	0.000523	0.00129	CcSEcCtD
Cefotaxime—Malaise—Doxorubicin—testicular cancer	0.000519	0.00128	CcSEcCtD
Cefotaxime—Leukopenia—Doxorubicin—testicular cancer	0.000515	0.00127	CcSEcCtD
Cefotaxime—Anaphylactic shock—Epirubicin—testicular cancer	0.000507	0.00126	CcSEcCtD
Cefotaxime—Shock—Epirubicin—testicular cancer	0.000499	0.00124	CcSEcCtD
Cefotaxime—Convulsion—Doxorubicin—testicular cancer	0.000498	0.00123	CcSEcCtD
Cefotaxime—Thrombocytopenia—Epirubicin—testicular cancer	0.000497	0.00123	CcSEcCtD
Cefotaxime—Discomfort—Doxorubicin—testicular cancer	0.000484	0.0012	CcSEcCtD
Cefotaxime—Anaphylactic shock—Doxorubicin—testicular cancer	0.000469	0.00116	CcSEcCtD
Cefotaxime—Pain—Methotrexate—testicular cancer	0.000463	0.00115	CcSEcCtD
Cefotaxime—Shock—Doxorubicin—testicular cancer	0.000462	0.00114	CcSEcCtD
Cefotaxime—Thrombocytopenia—Doxorubicin—testicular cancer	0.00046	0.00114	CcSEcCtD
Cefotaxime—Feeling abnormal—Methotrexate—testicular cancer	0.000447	0.00111	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Methotrexate—testicular cancer	0.000443	0.0011	CcSEcCtD
Cefotaxime—Pain—Epirubicin—testicular cancer	0.000434	0.00107	CcSEcCtD
Cefotaxime—Urticaria—Methotrexate—testicular cancer	0.000431	0.00107	CcSEcCtD
Cefotaxime—Abdominal pain—Methotrexate—testicular cancer	0.000428	0.00106	CcSEcCtD
Cefotaxime—Body temperature increased—Methotrexate—testicular cancer	0.000428	0.00106	CcSEcCtD
Cefotaxime—Feeling abnormal—Epirubicin—testicular cancer	0.000418	0.00104	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Epirubicin—testicular cancer	0.000415	0.00103	CcSEcCtD
Cefotaxime—Urticaria—Epirubicin—testicular cancer	0.000403	0.000998	CcSEcCtD
Cefotaxime—Pain—Doxorubicin—testicular cancer	0.000401	0.000994	CcSEcCtD
Cefotaxime—Abdominal pain—Epirubicin—testicular cancer	0.000401	0.000993	CcSEcCtD
Cefotaxime—Body temperature increased—Epirubicin—testicular cancer	0.000401	0.000993	CcSEcCtD
Cefotaxime—Hypersensitivity—Methotrexate—testicular cancer	0.000399	0.000989	CcSEcCtD
Cefotaxime—Feeling abnormal—Doxorubicin—testicular cancer	0.000387	0.000958	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000384	0.00095	CcSEcCtD
Cefotaxime—Pruritus—Methotrexate—testicular cancer	0.000383	0.00095	CcSEcCtD
Cefotaxime—Hypersensitivity—Epirubicin—testicular cancer	0.000374	0.000925	CcSEcCtD
Cefotaxime—Urticaria—Doxorubicin—testicular cancer	0.000373	0.000923	CcSEcCtD
Cefotaxime—Abdominal pain—Doxorubicin—testicular cancer	0.000371	0.000919	CcSEcCtD
Cefotaxime—Body temperature increased—Doxorubicin—testicular cancer	0.000371	0.000919	CcSEcCtD
Cefotaxime—Diarrhoea—Methotrexate—testicular cancer	0.000371	0.000918	CcSEcCtD
Cefotaxime—Pruritus—Epirubicin—testicular cancer	0.000359	0.000889	CcSEcCtD
Cefotaxime—Diarrhoea—Epirubicin—testicular cancer	0.000347	0.000859	CcSEcCtD
Cefotaxime—Hypersensitivity—Doxorubicin—testicular cancer	0.000346	0.000856	CcSEcCtD
Cefotaxime—Vomiting—Methotrexate—testicular cancer	0.000345	0.000853	CcSEcCtD
Cefotaxime—Rash—Methotrexate—testicular cancer	0.000342	0.000846	CcSEcCtD
Cefotaxime—Dermatitis—Methotrexate—testicular cancer	0.000341	0.000845	CcSEcCtD
Cefotaxime—Headache—Methotrexate—testicular cancer	0.00034	0.000841	CcSEcCtD
Cefotaxime—Pruritus—Doxorubicin—testicular cancer	0.000332	0.000822	CcSEcCtD
Cefotaxime—Vomiting—Epirubicin—testicular cancer	0.000323	0.000799	CcSEcCtD
Cefotaxime—Nausea—Methotrexate—testicular cancer	0.000322	0.000797	CcSEcCtD
Cefotaxime—Diarrhoea—Doxorubicin—testicular cancer	0.000321	0.000795	CcSEcCtD
Cefotaxime—Rash—Epirubicin—testicular cancer	0.00032	0.000792	CcSEcCtD
Cefotaxime—Dermatitis—Epirubicin—testicular cancer	0.00032	0.000791	CcSEcCtD
Cefotaxime—Headache—Epirubicin—testicular cancer	0.000318	0.000787	CcSEcCtD
Cefotaxime—Nausea—Epirubicin—testicular cancer	0.000301	0.000746	CcSEcCtD
Cefotaxime—Vomiting—Doxorubicin—testicular cancer	0.000298	0.000739	CcSEcCtD
Cefotaxime—Rash—Doxorubicin—testicular cancer	0.000296	0.000733	CcSEcCtD
Cefotaxime—Dermatitis—Doxorubicin—testicular cancer	0.000296	0.000732	CcSEcCtD
Cefotaxime—Headache—Doxorubicin—testicular cancer	0.000294	0.000728	CcSEcCtD
Cefotaxime—Nausea—Doxorubicin—testicular cancer	0.000279	0.00069	CcSEcCtD
